ORMP — Oramed Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $138.33m
- $12.43m
- $2.00m
Annual income statement for Oramed Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 August 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 2.7 | 2.7 | 1.34 | 0 | 2 |
| Cost of Revenue | |||||
| Gross Profit | — | — | — | — | 0.013 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 26.9 | 43.3 | 17.1 | 12.8 | 17.1 |
| Operating Profit | -24.2 | -40.6 | -15.8 | -12.8 | -15.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -23 | -37.7 | 5.09 | -15.9 | 75.3 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -23 | -37.8 | 5.09 | -19.1 | 64 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.2 | -36.6 | 5.53 | -19.1 | 64 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -22.2 | -36.6 | 5.53 | -19.1 | 64 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.781 | -0.938 | 0.136 | -0.467 | 1.51 |